Association of Adiponectin With biochemical parameters in patients with chronic kidney diseases on Hemodialysis process in Erbil city
DOI:
https://doi.org/10.21271/ZJPAS.35.1.19Keywords:
Adiponectin (Adipo.), chronic kidney disease (CKD), diabetes mellitus (DM), Glomerular Filtration Rate (GFR), C-reactive protein (CRP). Haemodialysis (HD).Abstract
Adiponectin (Adipo.) is a hormone produced by adipocytes that circulate in the blood. Serum Adipo. concentrations are elevated in several chronic kidney disease (CKD) conditions and are a predictor of end-stage renal disease. The association between Adipo. levels and the progression of the disease are not well established. This study aimed to determine if there was a relationship between serum Adipo. levels and inflammatory, metabolic, and CKD progression in Erbil. In a case-control study of 200 participants, 100 with CKDs were on hemodialysis (HD) in Erbil teaching hospital. To collect the necessary information from participants, a study questionnaire was used. Adipo. hormone levels and other metabolic parameters were measured. Total Cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), fasting blood sugar, C-reactive protein (CRP), glycosylated hemoglobin (HbA1c), creatinine, albumin, and urea were all measured in the blood. 90.0% of the cases were at stage 5 of CKD, the Serum Adipo. levels were higher when compared with a healthy control group (13.26 ±0.96 µg/ml vs 2.17±0.75 µg/ml). In conclusion, our study found A high level of Adipo. in CKD patients can predict inflammation and malnutrition and is considered a biomarker for renal dysfunction.
References
Achari, A.E., Jain, S.K., 2017. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. International Journal of Molecular Sciences 18. https://doi.org/10.3390/ijms18061321
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K.,
Shimomura, I., Nakamura, T., Miyaoka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo, K., Matsubara, K., Muraguchi, M., Ohmoto, Y., Funahashi, T., Matsuzawa, Y., 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79–83. https://doi.org/10.1006/bbrc.1999.0255
Attman, P.-O.A., Samuelsson, O.G., Moberly, J., Johansson, A.-C., Ljungman, S., Weiss, L.G., Knight-Gibson, C., Alaupovic, P., 1999. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney international 55, 1536–1542.
Azra, K., 2014. ESTIMATION OF BLOOD UREA (BUN) AND SERUM CREATININE LEVEL IN PATIENTS OF RENAL DISORDER. Indian Journal of Fundamental and Applied Life Sciences Vol. 4, 199–202.
Balsan, G.A., Vieira, J.L. da C., Oliveira, A.M. de, Portal, V.L., 2015. Relationship between adiponectin, obesity and insulin resistance. Revista da Associação Médica Brasileira 61, 72–80.
Baratta, R., Amato, S., Degano, C., Farina, M.G., Patanè, G., Vigneri, R., Frittitta, L., 2004. Adiponectin Relationship with Lipid Metabolism Is Independent of Body Fat Mass: Evidence from Both Cross-Sectional and Intervention Studies. The Journal of Clinical Endocrinology & Metabolism 89, 2665–2671. https://doi.org/10.1210/jc.2003-031777
Barcellos, F.C., Santos, I.S., Umpierre, D., Bohlke, M., Hallal, P.C., 2015. Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clinical kidney journal 8, 753–765.
Baria, D., Joshi, V.S., Shah, T.D., Gandha, K.M., Modi, N., 2013. Impact of Hemodialysis on Lipid Profile among Chronic Renal Failure Patients - A Case-Control Study.
Bello, A.K., Nwankwo, E., El Nahas, A.M., 2005. Prevention of chronic kidney disease: a global challenge. Kidney International 68, S11–S17.
Bloomgarden, Z., Handelsman, Y., 2017. How does CKD affect HbA1c? Journal of diabetes 10, 270–270.
Bologa, R., Levine, D., Parker, T., Cheigh, J., Serur, D., Stenzel, K., Rubin, A., 1998. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. American Journal of Kidney Diseases 32, 107–114. https://doi.org/10.1053/ajkd.1998.v32.pm9669431
Brito, F., Almeida, S., Figueredo, C., Bregman, R., Suassuna, J., Fischer, R., 2012. Extent and severity of chronic periodontitis in chronic kidney disease patients. Journal of periodontal research 47, 426–430.
Chapter 1: Definition and classification of CKD, 2013. . Kidney Int Suppl (2011) 3, 19–62. https://doi.org/10.1038/kisup.2012.64
Chow, W.-S., Cheung, B.M.Y., Tso, A.W.K., Xu, A., Wat, N.M.S., Fong, C.H.Y., Ong, L.H.Y., Tam, S., Tan, K.C.B., Janus, E.D., Lam, T.-H., Lam, K.S.L., 2007. Hypoadiponectinemia as a Predictor for the Development of Hypertension. Hypertension 49, 1455–1461. https://doi.org/10.1161/HYPERTENSIONAHA.107.086835
Christou, G.A., Kiortsis, D.N., 2014a. The role of adiponectin in renal physiology and development of albuminuria. Journal of Endocrinology 221, R49–R61. https://doi.org/10.1530/JOE-13-0578
Christou, G.A., Kiortsis, D.N., 2014b. The role of adiponectin in renal physiology and development of albuminuria. J Endocrinol 221, R49-61. https://doi.org/10.1530/JOE-13-0578
Cnop, M., Havel, P.J., Utzschneider, K.M., Carr, D.B., Sinha, M.K., Boyko, E.J., Retzlaff, B.M., Knopp, R.H., Brunzell, J.D., Kahn, S.E., 2003. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46,
–469. https://doi.org/10.1007/s00125-003-1074-z
Combs, T.P., Berg, A.H., Obici, S., Scherer, P.E., Rossetti, L., 2001. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. The Journal of clinical investigation 108, 1875–1881.
de Carvalho, C.P., Marin, D.M., de Souza, A.L., Pareja, J.C., Chaim, E.A., de Barros Mazon, S., da Silva, C.A., Geloneze, B., Muscelli, E., Alegre, S.M., 2009. GLP-1 and Adiponectin: Effect of Weight Loss After Dietary Restriction and Gastric Bypass in Morbidly Obese Patients with Normal and Abnormal Glucose Metabolism. Obesity Surgery 19, 313–320. https://doi.org/10.1007/s11695-008-9678-5
Drueke, T., Lacour, B., 1995. Lipid metabolism. Massary and Glassocks Textbook of Nephrology. Baltimore, William, and Wilkins.
Elamouri, J.S., 2021. Family history in patients with end-stage renal disease on hemodialysis in Tripoli, Libya. Ibnosina Journal of Medicine and Biomedical Sciences 13, 14.
Fink, J.C., Burdick, R.A., Kurth, S.J., Blahut, S.A., Armistead, N.C., Turner, M.S., Shickle, L.M., Light, P.D., 1999. Significance of serum creatinine values in new end-stage renal disease patients. American Journal of Kidney Diseases 34, 694–701. https://doi.org/10.1016/S0272-6386(99)70395-1
Freedman, B.I., Volkova, N.V., Satko, S.G., Krisher, J., Jurkovitz, C., Soucie, J.M., McClellan, W.M., 2005. Population-based screening for family history of end-stage renal disease among incident dialysis patients. American journal of nephrology 25, 529–535.
Halberg, N., Schraw, T.D., Wang, Z.V., Kim, J.-Y., Yi, J., Hamilton, M.P., Luby-Phelps, K., Scherer, P.E., 2009. Systemic Fate of the Adipocyte-Derived Factor Adiponectin. Diabetes 58, 1961–1970. https://doi.org/10.2337/db08-1750
Hellberg, M., Höglund, P., Svensson, P., Clyne, N., 2019. Randomized controlled trial of exercise in CKD—the RENEXC study. Kidney international reports 4, 963–976.
Hernandez, D., Espejo-Gil, A., Bernal-Lopez, M.R., Mancera-Romero, J., Baca-Osorio, A.J., Tinahones, F.J., Armas-Padron, A.M., Ruiz-Esteban, P., Torres, A., Gomez-Huelgas, R., 2013. Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrology 14, 151. https://doi.org/10.1186/1471-2369-14-151
Hirako, S., 2016. Subchapter 34B - Adiponectin, in: Takei, Y., Ando, H., Tsutsui, K. (Eds.), Handbook of Hormones. Academic Press, San Diego, pp. 308-e34B-5. https://doi.org/10.1016/B978-0-12-801028-0.00192-6
Johnson, C.A., Levey, A.S., Coresh, J., Levin, A., Eknoyan, J.G.L., 2004. Clinical practice guidelines for chronic kidney disease in adults: part 1. Definition, disease stages, evaluation, treatment, and risk factors. American family physician 70, 869–876.
Kamal, A., 2014. Estimation of blood urea (BUN) and serum creatinine level in patients of renal disorder. Indian J Fundam Appl Life Sci 4, 199–202.
Kaysen, G.A., Dubin, J.A., Müller, H.-G., Rosales, L., Levin, N.W., Mitch, W.E., the HEMO Study Group, 2004. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney International 65, 1408–1415. https://doi.org/10.1111/j.1523-1755.2004.00520.x
Kilpatrick, R.D., McAllister, C.J., Kovesdy, C.P., Derose, S.F., Kopple, J.D., Kalantar-Zadeh, K., 2007. Association between serum lipids and survival in hemodialysis patients and impact of race. Journal of the American Society of Nephrology 18, 293–303.
Kim, H.Y., Bae, E.H., Ma, S.K., Chae, D.W., Choi, K.H., Kim, Y.-S., Hwang, Y.-H., Ahn, C., Kim, S.W., 2016. Association
Achari, A.E., Jain, S.K., 2017. Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction. International Journal of Molecular Sciences 18. https://doi.org/10.3390/ijms18061321
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., Kuriyama, H., Nishida, M., Yamashita, S., Okubo, K., Matsubara, K., Muraguchi, M., Ohmoto, Y., Funahashi, T., Matsuzawa, Y., 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79–83. https://doi.org/10.1006/bbrc.1999.0255
Attman, P.-O.A., Samuelsson, O.G., Moberly, J., Johansson, A.-C., Ljungman, S., Weiss, L.G., Knight-Gibson, C., Alaupovic, P., 1999. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney international 55, 1536–1542.
Azra, K., 2014. ESTIMATION OF BLOOD UREA (BUN) AND SERUM CREATININE LEVEL IN PATIENTS OF RENAL DISORDER. Indian Journal of Fundamental and Applied Life Sciences Vol. 4, 199–202.
Balsan, G.A., Vieira, J.L. da C., Oliveira, A.M. de, Portal, V.L., 2015. Relationship between adiponectin, obesity and insulin resistance. Revista da Associação Médica Brasileira 61, 72–80.
Baratta, R., Amato, S., Degano, C., Farina, M.G., Patanè, G., Vigneri, R., Frittitta, L., 2004. Adiponectin Relationship with Lipid Metabolism Is Independent of Body Fat Mass: Evidence from Both Cross-Sectional and Intervention Studies. The Journal of Clinical Endocrinology & Metabolism 89, 2665–2671. https://doi.org/10.1210/jc.2003-031777
Barcellos, F.C., Santos, I.S., Umpierre, D., Bohlke, M., Hallal, P.C., 2015. Effects of exercise in the whole spectrum of chronic kidney disease: a systematic review. Clinical kidney journal 8, 753–765.
Baria, D., Joshi, V.S., Shah, T.D., Gandha, K.M., Modi, N., 2013. Impact of Hemodialysis on Lipid Profile among Chronic Renal Failure Patients - A Case-Control Study.
Bello, A.K., Nwankwo, E., El Nahas, A.M., 2005. Prevention of chronic kidney disease: a global challenge. Kidney International 68, S11–S17.
Bloomgarden, Z., Handelsman, Y., 2017. How does CKD affect HbA1c? Journal of diabetes 10, 270–270.
Bologa, R., Levine, D., Parker, T., Cheigh, J., Serur, D., Stenzel, K., Rubin, A., 1998. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. American Journal of Kidney Diseases 32, 107–114. https://doi.org/10.1053/ajkd.1998.v32.pm9669431
Brito, F., Almeida, S., Figueredo, C., Bregman, R., Suassuna, J., Fischer, R., 2012. Extent and severity of chronic periodontitis in chronic kidney disease patients. Journal of periodontal research 47, 426–430.
Chapter 1: Definition and classification of CKD, 2013. . Kidney Int Suppl (2011) 3, 19–62. https://doi.org/10.1038/kisup.2012.64
Chow, W.-S., Cheung, B.M.Y., Tso, A.W.K., Xu, A., Wat, N.M.S., Fong, C.H.Y., Ong, L.H.Y., Tam, S., Tan, K.C.B., Janus, E.D., Lam, T.-H., Lam, K.S.L., 2007. Hypoadiponectinemia as a Predictor for the Development of Hypertension. Hypertension 49, 1455–1461. https://doi.org/10.1161/HYPERTENSIONAHA.107.086835
Christou, G.A., Kiortsis, D.N., 2014a. The role of adiponectin in renal physiology and development of albuminuria. Journal of Endocrinology 221, R49–R61. https://doi.org/10.1530/JOE-13-0578
Christou, G.A., Kiortsis, D.N., 2014b. The role of adiponectin in renal physiology and development of albuminuria. J Endocrinol 221, R49-61. https://doi.org/10.1530/JOE-13-0578
Cnop, M., Havel, P.J., Utzschneider, K.M., Carr, D.B., Sinha, M.K., Boyko, E.J., Retzlaff, B.M., Knopp, R.H., Brunzell, J.D., Kahn, S.E., 2003. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46, 459–469. https://doi.org/10.1007/s00125-003-1074-z
Combs, T.P., Berg, A.H., Obici, S., Scherer, P.E., Rossetti, L., 2001. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. The Journal of clinical investigation 108, 1875–1881.
de Carvalho, C.P., Marin, D.M., de Souza, A.L., Pareja, J.C., Chaim, E.A., de Barros Mazon, S., da Silva, C.A., Geloneze, B., Muscelli, E., Alegre, S.M., 2009. GLP-1 and Adiponectin: Effect of Weight Loss After Dietary Restriction and Gastric Bypass in Morbidly Obese Patients with Normal and Abnormal Glucose Metabolism. Obesity Surgery 19, 313–320. https://doi.org/10.1007/s11695-008-9678-5
Drueke, T., Lacour, B., 1995. Lipid metabolism. Massary and Glassocks Textbook of Nephrology. Baltimore, William, and Wilkins.
Elamouri, J.S., 2021. Family history in patients with end-stage renal disease on hemodialysis in Tripoli, Libya. Ibnosina Journal of Medicine and Biomedical Sciences 13, 14.
Fink, J.C., Burdick, R.A., Kurth, S.J., Blahut, S.A., Armistead, N.C., Turner, M.S., Shickle, L.M., Light, P.D., 1999. Significance of serum creatinine values in new end-stage renal disease patients. American Journal of Kidney Diseases 34, 694–701. https://doi.org/10.1016/S0272-6386(99)70395-1
Freedman, B.I., Volkova, N.V., Satko, S.G., Krisher, J., Jurkovitz, C., Soucie, J.M., McClellan, W.M., 2005. Population-based screening for family history of end-stage renal disease among incident dialysis patients. American journal of nephrology 25, 529–535.
Halberg, N., Schraw, T.D., Wang, Z.V., Kim, J.-Y., Yi, J., Hamilton, M.P., Luby-Phelps, K., Scherer, P.E., 2009. Systemic Fate of the Adipocyte-Derived Factor Adiponectin. Diabetes 58, 1961–1970. https://doi.org/10.2337/db08-1750
Hellberg, M., Höglund, P., Svensson, P., Clyne, N., 2019. Randomized controlled trial of exercise in CKD—the RENEXC study. Kidney international reports 4, 963–976.
Hernandez, D., Espejo-Gil, A., Bernal-Lopez, M.R., Mancera-Romero, J., Baca-Osorio, A.J., Tinahones, F.J., Armas-Padron, A.M., Ruiz-Esteban, P., Torres, A., Gomez-Huelgas, R., 2013. Association of HbA1c and cardiovascular and renal disease in an adult Mediterranean population. BMC Nephrology 14, 151. https://doi.org/10.1186/1471-2369-14-151
Hirako, S., 2016. Subchapter 34B - Adiponectin, in: Takei, Y., Ando, H., Tsutsui, K. (Eds.), Handbook of Hormones. Academic Press, San Diego, pp. 308-e34B-5. https://doi.org/10.1016/B978-0-12-801028-0.00192-6
Johnson, C.A., Levey, A.S., Coresh, J., Levin, A., Eknoyan, J.G.L., 2004. Clinical practice guidelines for chronic kidney disease in adults: part 1. Definition, disease stages, evaluation, treatment, and risk factors. American family physician 70, 869–876.
Kamal, A., 2014. Estimation of blood urea (BUN) and serum creatinine level in patients of renal disorder. Indian J Fundam Appl Life Sci 4, 199–202.
Kaysen, G.A., Dubin, J.A., Müller, H.-G., Rosales, L., Levin, N.W., Mitch, W.E., the HEMO Study Group, 2004. Inflammation and reduced albumin synthesis associated with stable decline in serum albumin in hemodialysis patients. Kidney International 65, 1408–1415. https://doi.org/10.1111/j.1523-1755.2004.00520.x
Kilpatrick, R.D., McAllister, C.J., Kovesdy, C.P., Derose, S.F., Kopple, J.D., Kalantar-Zadeh, K., 2007. Association between serum lipids and survival in hemodialysis patients and impact of race. Journal of the American Society of Nephrology 18, 293–303.
Kim, H.Y., Bae, E.H., Ma, S.K., Chae, D.W., Choi, K.H., Kim, Y.-S., Hwang, Y.-H., Ahn, C., Kim, S.W., 2016. Association of serum adiponectin level with albuminuria in chronic kidney disease patients. Clinical and Experimental Nephrology 20, 443–449. https://doi.org/10.1007/s10157-015-1173-4
Kim, Y., Park, C.W., 2019. Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease. Int J Mol Sci 20, 1782. https://doi.org/10.3390/ijms20071782
Kim, Y., Park, C.W., 2017. New therapeutic agents in diabetic nephropathy. Korean J Intern Med 32, 11–25. https://doi.org/10.3904/kjim.2016.174
Kosmadakis, G.C., Bevington, A., Smith, A.C., Clapp, E.L., Viana, J.L., Bishop, N.C., Feehally, J., 2010. Physical Exercise in Patients with Severe Kidney Disease. Nephron Clinical Practice 115, c7–c16. https://doi.org/10.1159/000286344
Kuo, I.-C., Wu, P.-H., Lin, H.Y.-H., Niu, S.-W., Huang, J.-C., Hung, C.-C., Chiu, Y.-W., Chen, H.-C., 2019. The association of adiponectin with metabolic syndrome and clinical outcome in patients with non-diabetic chronic kidney disease. PLoS One 14, e0220158.
Lacquaniti, A., Bolignano, D., Donato, V., Bono, C., Fazio, M., Buemi, M., 2010. Alterations of Lipid Metabolism in Chronic Nephropathies: Mechanisms, Diagnosis and Treatment. Kidney & blood pressure research 33, 100–10. https://doi.org/10.1159/000302712
Lee, S.-Y., Chen, Y.-C., Tsai, I.-C., Yen, C.-J., Chueh, S.-N., Chuang, H.-F., Wu, H.-Y., Chiang, C.-K., Cheng, H.-T., Hung, K.-Y., Huang, J.-W., 2013. Glycosylated Hemoglobin and Albumin-Corrected Fructosamine Are Good Indicators for Glycemic Control in Peritoneal Dialysis Patients. PloS one 8, e57762. https://doi.org/10.1371/journal.pone.0057762
Levey, A., Greene, T., Kusek, J., Beck, G., MDRD Study Group, 2000. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11, 155.
Lowrie, E.G., Lew, N.L., 1990. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. American Journal of Kidney Diseases 15, 458–482.
Mallamaci, F., Pisano, A., Tripepi, G., 2020. Physical activity in chronic kidney disease and the EXerCise Introduction To Enhance trial. Nephrology Dialysis Transplantation 35, ii18–ii22. https://doi.org/10.1093/ndt/gfaa012
Matsuda, M., Shimomura, I., 2014. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Reviews in endocrine and metabolic disorders 15, 1–10.
Matsuda, M., Shimomura, I., Sata, M., Arita, Y., Nishida, M., Maeda, N., Kumada, M., Okamoto, Y., Nagaretani, H., Nishizawa, H., Kishida, K., Komuro, R., Ouchi, N., Kihara, S., Nagai, R., Funahashi, T., Matsuzawa, Y., 2002. Role of Adiponectin in Preventing Vascular Stenosis: THE MISSING LINK OF ADIPO-VASCULAR AXIS *. Journal of Biological Chemistry 277, 37487–37491. https://doi.org/10.1074/jbc.M206083200
Menon, V., Li, L., Wang, X., Greene, T., Balakrishnan, V., Madero, M., Pereira, A.A., Beck, G.J., Kusek, J.W., Collins, A.J., Levey, A.S., Sarnak, M.J., 2006. Adiponectin and Mortality in Patients with Chronic Kidney Disease. J. Am. Soc. Nephrol. 17, 2599. https://doi.org/10.1681/ASN.2006040331
Miller, R.A., Chu, Q., Le Lay, J., Scherer, P.E., Ahima, R.S., Kaestner, K.H., Foretz, M., Viollet, B., Birnbaum, M.J., 2011. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. The Journal of clinical investigation 121, 2518–2528.
Moses, O., Johnkennedy, N., 2013. Alteration of serum glucose, urea and creatinine level of malaria patients in Obowo, Local Government Area of Imo state Nigeria. Int J Adv Med 1, 1–6.
Nadeem, M., Stephen, L., Schubert, C., Davids, M., 2009. Association between periodontitis and systemic inflammation in patients with end-stage renal disease. South African Dental Journal 64, 470–473.
Näsström, B., Olivecrona, G., Olivecrona, T., Stegmayr, B.G., 2003. Lipoprotein lipase during heparin infusion: lower activity in hemodialysis patients. Scandinavian journal of clinical and laboratory investigation 63, 45–54.
Näsström, B., Stegmayr, B., Gupta, J., Olivecrona, G., Olivecrona, T., 2005. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrology Dialysis Transplantation 20, 1172–1179.
Okamoto, Y., Kihara, S., Ouchi, N., Nishida, M., Arita, Y., Kumada, M., Ohashi, K., Sakai, N., Shimomura, I., Kobayashi, H., 2002. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106, 2767–2770.
Orchard, T.J., Chang, Y.-F., Ferrell, R.E., Petro, N., Ellis, D.E., 2002. Nephropathy in type 1 diabetes: A manifestation of insulin resistance and multiple genetic susceptibilities?: Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney international 62, 963–970.
Pejcic, A., Kesic, L., Milasin, J., 2011. C-reactive protein as a systemic marker of inflammation in periodontitis. European journal of clinical microbiology & infectious diseases 30, 407–414.
Perri, A., Vizza, D., Lofaro, D., Gigliotti, P., Leone, F., Brunelli, E., Malivindi, R., De Amicis, F., Romeo, F., De Stefano, R., Papalia, T., Bonofiglio, R., 2013. Adiponectin is expressed and secreted by renal tubular epithelial cells. Journal of nephrology 26, 1049—1054. https://doi.org/10.5301/jn.5000269
Rao, M., Jaber, B.L., Balakrishnan, V.S., 2006. UNRESOLVED ISSUES IN DIALYSIS: Inflammatory Biomarkers and Cardiovascular Risk: Association or Cause and Effect? Presented at the Seminars in dialysis, Wiley Online Library, pp. 129–135.
Rhee, C.M., Nguyen, D.V., Moradi, H., Brunelli, S.M., Dukkipati, R., Jing, J., Nakata, T., Kovesdy, C.P., Brent, G.A., Kalantar-Zadeh, K., 2015. Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. American Journal of Kidney Diseases 66, 313–321. https://doi.org/10.1053/j.ajkd.2015.02.325
Riwanto, M., Rohrer, L., Eckardstein, A. von, Landmesser, U., 2015. Dysfunctional HDL: from structure-function-relationships to biomarkers. High Density Lipoproteins 337–366.
Robinson-Cohen, C., Littman, A.J., Duncan, G.E., Roshanravan, B., Ikizler, T.A., Himmelfarb, J., Kestenbaum, B.R., 2013. Assessment of Physical Activity in Chronic Kidney Disease. Journal of Renal Nutrition 23, 123–131. https://doi.org/10.1053/j.jrn.2012.04.008
Saraheimo, M., Teppo, A.-M., Forsblom, C., Fagerudd, J., Groop, P.-H., on behalf of the FinnDiane Study Group, 2003. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 46, 1402–1407. https://doi.org/10.1007/s00125-003-1194-5
Schaeffner, E.S., Kurth, T., Curhan, G.C., Glynn, R.J., Rexrode, K.M., Baigent, C., Buring, J.E., Gaziano, J.M., 2003. Cholesterol and the risk of renal dysfunction in apparently healthy men. Journal of the American Society of Nephrology 14, 2084–2091.
Sedighi, O., Abediankenari, S., 2013. Relationship between plasma adiponectin level with inflammatory and metabolic markers in patients with chronic kidney disease. Nephrourol Mon 6, e11743–e11743. https://doi.org/10.5812/numonthly.11743
Shahbaz, H., Gupta, M., 2021. Creatinine Clearance. StatPearls Publishing, Treasure Island (FL).
Sharma, A., Hirulkar, N., Wadel, P., Das, P., 2011. Influence of hyperglycemia on renal function parameters in patients with diabetes mellitus. IJPBA 2, 734–9.
Shavit, L., Lifschitz, M., Galperin, I., 2012. Influence of enteric nutrition on blood urea nitrogen (BUN) in very old patients with chronic kidney disease (CKD). Archives of Gerontology and Geriatrics 54, 228–231. https://doi.org/10.1016/j.archger.2011.03.007
Shimada, K., Miyazaki, T., Daida, H., 2004. Adiponectin and atherosclerotic disease. Clinica Chimica Acta 344, 1–12. https://doi.org/10.1016/j.cccn.2004.02.020
Singh, S., Pathak, A., Parappanavar, N.U., 2019. A study of fasting lipid profile in chronic kidney disease patients.
Swarbrick, M.M., Havel, P.J., 2008. Physiological, Pharmacological, and Nutritional Regulation of Circulating Adiponectin Concentrations in Humans. Metabolic Syndrome and Related Disorders 6, 87–102. https://doi.org/10.1089/met.2007.0029
Tsao, T.-S., Murrey, H.E., Hug, C., Lee, D.H., Lodish, H.F., 2002. Oligomerization State-dependent Activation of NF-κB Signaling Pathway by Adipocyte Complement-related Protein of 30 kDa (Acrp30) *. Journal of Biological Chemistry 277, 29359–29362. https://doi.org/10.1074/jbc.C200312200
Tward, A., Xia, Y.-R., Wang, X.-P., Shi, Y.-S., Park, C., Castellani, L.W., Lusis, A.J., Shih, D.M., 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106, 484–490.
Vaziri, N., 2006. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. American Journal of Physiology-Renal Physiology 290, F262–F272.
Vaziri, N.D., 2010. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. Journal of Renal Nutrition 20, S35–S43.
Welters, I.D., Bing, C., Ding, C., Leuwer, M., Hall, A.M., 2014. Circulating anti-inflammatory adipokines High Molecular Weight Adiponectin and Zinc-α2-glycoprotein (ZAG) are inhibited in early sepsis, but increase with clinical recovery: a pilot study. BMC anesthesiology 14, 1–10.
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature medicine 7, 941–946.
Yeun, J.Y., Kaysen, G.A., 1997. Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin in peritoneal dialysis patients. American Journal of Kidney Diseases 30, 923–927. https://doi.org/10.1016/S0272-6386(97)90105-0
Yoo, H.H.B., Martin, L.C., Kochi, A.C., Rodrigues-Telini, L.S., Barretti, P., Caramori, J.T., Matsubara, B.B., Zannati-Bazan, S.G., da Silva Franco, R.J., Queluz, T.T., 2012. Could albumin level explain the higher mortality in hemodialysis patients with pulmonary hypertension? BMC nephrology 13, 1–7.
Zoccali, C., Mallamaci, F., Panuccio, V., Tripepi, G., Cutrupi, S., Parlongo, S., Catalano, F., Tanaka, S., Ouchi, N., Kihara, S., Funahashi, T., Matsuzawa, Y., 2003. Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney International 63, S98–S102. https://doi.org/10.1046/j.1523-1755.63.s84.49.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jwan Qader Azeez , Dler Qader Gallaly
This work is licensed under a Creative Commons Attribution 4.0 International License.
